An overview of the patterns of prescription opioid use, costs and related harms in Australia

被引:166
作者
Blanch, Bianca [1 ]
Pearson, Sallie-Anne [1 ,2 ]
Haber, Paul S. [2 ,3 ]
机构
[1] Univ Sydney, Fac Pharm, Pharmacoepidemiol & Pharmaceut Policy Res Grp, Sydney, NSW 2006, Australia
[2] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia
[3] Royal Prince Alfred Hosp, Sydney Med Sch, Drug Hlth Serv, Sydney, NSW 2050, Australia
关键词
Australia; death; drug utilization; factual databases; hospitalization; opioid analgesics; NONMEDICAL USE; OVERDOSE DEATHS; NONCANCER PAIN; TRENDS; ANALGESICS; ABUSE; OXYCODONE; CONSEQUENCES; CONSUMPTION; EPIDEMIC;
D O I
10.1111/bcp.12446
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
AimsTo report Australian population trends in subsidized prescribed opioid use, total costs to the Australian government to subsidize these medicines and opioid-related harms based on hospitalizations and accidental poisoning deaths. MethodsWe utilized three national aggregated data sources including dispensing claims from the Pharmaceutical Benefits Scheme, opioid-related hospitalizations from the National Hospital Morbidity Database and accidental poisoning deaths from the Australian Bureau of Statistics. ResultsBetween 1992 and 2012, opioid dispensing episodes increased 15-fold (500000 to 7.5 million) and the corresponding cost to the Australian government increased 32-fold ($8.5 million to $271 million). Opioid-related harms also increased. Opioid-related hospitalizations increased from 605 to 1464 cases (1998-2009), outnumbering hospitalizations due to heroin poisonings since 2001. Deaths due to accidental poisoning (pharmaceutical opioids and illicit substances combined) increased from 151 to 266 (2002-2011), resulting in a rise in the death rate of 0.78 to 1.19 deaths/100000 population over 10 years. Death rates increased 1.8 fold in males and 1.4 fold in females. ConclusionsThe striking increase in opioid use and related harms in Australia is consistent with trends observed in other jurisdictions. Further, there is no evidence to suggest these increases are plateauing. There is currently limited evidence in Australia about individual patterns of opioid use and the associated risk of adverse events. Further research should focus on these important issues so as to provide important evidence supporting effective change in policy and practice.
引用
收藏
页码:1159 / 1166
页数:8
相关论文
共 46 条
[1]
[Anonymous], 2012, The WHO application of ICD-10 to deaths during pregnancy, childbirth and the puerperium: IDC-MM
[2]
[Anonymous], VIT SIGNS PRESCR PAI
[3]
Australian Bureau of Statistics, 2012, CHAR BOD PAIN AUSTR
[4]
Australian Bureau of Statistics, 2009, CAUS DEATH
[5]
Australian Government Department of Health, PBAC OUTC
[6]
Australian Institute of Health and Welfare, SEP STAT PRINC DIAGN
[7]
Australian Institute of Health and Welfare, 2013, SEP STAT PRINC DIAGN
[8]
Chronic opioid therapy and its utility in different populations [J].
Ballantyne, Jane C. .
PAIN, 2012, 153 (12) :2303-2304
[9]
Australian trends in opioid prescribing for chronic non-cancer pain, 1986-1996 [J].
Bell, JR .
MEDICAL JOURNAL OF AUSTRALIA, 1997, 167 (01) :26-29
[10]
Trends in licit opioid use in Australia, 1984-1998: comparative analysis of international and jurisdictional data [J].
Berbatis, CG ;
Sunderland, VB ;
Bulsara, M ;
Lintzeris, N .
MEDICAL JOURNAL OF AUSTRALIA, 2000, 173 (10) :524-527